Jørgensen Karsten Juhl, Johansson Minna, Woloshin Steven
Cochrane Denmark and Centre for Evidence-Based Medicine Odense, University of Southern Denmark, Odense, Denmark.
Lisa Schwartz Foundation for Truth in Medicine, Norwich, VT, USA.
BMC Med. 2025 Apr 24;23(1):242. doi: 10.1186/s12916-025-04081-3.
Authors of a matched cohort study claimed the NHS Health Check programme reduced total mortality 23% and liver cirrhosis incidence 44%. Such impressive results require critical scrutiny, especially as the intervention targets a large, predominantly healthy population, and as it has harms and costs. Eleven high-quality randomised trials containing varying combinations of the elements constituting the NHS Health Check assessed total mortality. They included 233,298 participants and 21,535 deaths, with a risk ratio for total mortality of 1.00 (95% CI 0.97 to 1.03) and little or no effect on mortality from targeted diseases, including cardiovascular disease. However, the observational study did not reference any of those trials. No harms, though well-known, were assessed or mentioned. While some limitations were discussed, others were not and central questions regarding the likelihood of their results were not asked. A burden of proof must be met before interventions are introduced, especially those directed towards healthy citizens that divert resources away from medical and non-medical interventions of known benefit. In our opinion, the NHS Health Check programme does not meet UK National Screening Committee requirements that high-quality randomized trials show benefits outweigh harms. Emphasizing evidence from observational studies while disregarding randomised trials that contradict their findings and failing to assess or mention harms of interventions directed at healthy citizens, are contrary to sound scientific principles, and to evidence-based medicine. This apparently guides policies which burden an already stressed health system. A review of the NHS Health Check programme by the UK National Screening Committee seems timely.
一项配对队列研究的作者声称,国民保健服务(NHS)健康检查计划使总死亡率降低了23%,肝硬化发病率降低了44%。如此令人印象深刻的结果需要严格审查,尤其是因为该干预措施针对的是大量主要健康的人群,而且它存在危害和成本。11项高质量随机试验评估了总死亡率,这些试验包含了构成NHS健康检查的不同要素组合。试验纳入了233,298名参与者,21,535人死亡,总死亡率的风险比为1.00(95%置信区间0.97至1.03),对包括心血管疾病在内的目标疾病的死亡率几乎没有影响。然而,该观察性研究并未引用这些试验中的任何一项。虽然一些危害是众所周知的,但并未进行评估或提及。虽然讨论了一些局限性,但其他局限性未被讨论,也未就其结果的可能性提出核心问题。在引入干预措施之前,尤其是那些针对健康公民且将资源从已知有益的医疗和非医疗干预措施中转移出来的干预措施,必须满足举证责任。我们认为,NHS健康检查计划不符合英国国家筛查委员会的要求,即高质量随机试验应证明益处大于危害。强调观察性研究的证据而忽视与其结果相矛盾的随机试验,并且未能评估或提及针对健康公民的干预措施的危害,这违背了合理的科学原则和循证医学。这显然指导了给本已不堪重负的卫生系统增加负担的政策。英国国家筛查委员会对NHS健康检查计划进行审查似乎很及时。